BioSpace News Archive

OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended June 30, 2021, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, July 29, 2021.

First clinical dosing of a compound using PN backbone chemistry modifications Enrolling participants with C9-ALS, C9-FTD or mixed phenotype FOCUS-C9 is adaptive to enable rapid optimization of WVE-004 dosing

Kineta to leverage Samsung Biologics’ development and manufacturing expertise to advance KVA12.1 to IND Samsung Biologics San Francisco R&D center and South Korea headquarters to offer a seamless, end-to-end CDMO service.

As part of a continued growth strategy, Health Monitor is strengthening its digital data analytics capabilities with new product innovations and a major leadership addition

OpRegen ® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy

ENDRA Life Sciences Inc., a pioneer of Thermo Acoustic Enhanced UltraSound, announces that management will participate in A.G.P.'s Virtual MedTech Summer Conference on Thursday, July 29, 2021.

Neuronetics, Inc. today announced that it plans to release second quarter financial and operating results prior to market open on Tuesday, August 3, 2021.

Varex Imaging Corporation (Nasdaq: VREX) today announced that it will report unaudited financial results for the third quarter of fiscal year 2021 following the close of regular trading on Tuesday, August 3, 2021.

Phase 1b study data demonstrate non-invasive white matter imaging enables better drug targeting in specific areas of the brain

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for PROGRAF® (tacrolimus) for the prevention of organ rejection in adult and pediatric lung transplant recipients.